ArticleArchiv der Pharmazie2026
A Proteochemometric Model for Ligands of the SLC5 Transporter Family.
Article in Archiv der Pharmazie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The SLC5 family of solute carriers is of significant interest for drug development due to its role in many disease processes. Building on the recent elucidation of SGLT2's structure, we developed a proteochemometric model for SLC5 inhibitors in order to gain information on selectivity-driving amino acids in the binding site. Ensemble-based algorithms, namely random forest (RF) and gradient-boosted trees, proved the best suited for the task reaching high accuracy in both activity and selectivity predictions with Morgan circular fingerprints and Z-scales for ligand and protein features, respectively. Inclusion of protein sequence as input parameters for the PCM modeling allowed identification of Leu286 in hSLGT2 as a new potential key binding site residue crucial for selectivity. Furthermore, the PCM model also performed well in predicting the effect of single-point mutations at hSGLT2 on the binding affinity of empagliflozin. The obtained models are available in the form of a Jupyter notebook.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.